SCHEMBL2188979

SCHEMBL2188979

N[C@H]1CCC(=O)N[C@H]1c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.49
MDM2 Q00987 1/20 0.49
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
MAOB P27338 8/20 0.39
MAOA P21397 7/20 0.39
KDM1A O60341 5/20 0.39
CYP2C19 P33261 4/20 0.39
CYP2B6 P20813 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
LMNA P02545 2/20 0.39
TAAR1 Q96RJ0 2/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188987 1.00 TP53 (0.49) TP53MDM2DDB1CRBNGAA
SCHEMBL8537685 1.00 TP53 (0.49) TP53MDM2DDB1CRBNGAA
SCHEMBL8537684 1.00 TP53 (0.49) TP53MDM2DDB1CRBNGAA
SCHEMBL2188994 1.00 TP53 (0.49) TP53MDM2DDB1CRBNGAA
Hydrochloric Acid SCHEMBL6818558 0.98 TP53 (0.48) TP53MDM2DDB1CRBNGAA
SCHEMBL8631315 0.83 TDP1 (0.45) TP53MDM2DDB1CRBNSMN1; SMN2
SCHEMBL2189767 0.83 TP53 (0.43) TP53MDM2DDB1CRBNGAA
SCHEMBL2189775 0.83 TP53 (0.43) TP53MDM2DDB1CRBNGAA
SCHEMBL2189771 0.83 TP53 (0.43) TP53MDM2DDB1CRBNGAA
SCHEMBL2190043 0.83 TP53 (0.43) TP53MDM2DDB1CRBNGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2361246-A1 OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS Pfizer Inc. (US) 2011-08-31 EP disclosed
US-20110172297-A1 Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof PFIZER INC 2011-07-14 US disclosed
WO-2010038167-A1 OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS PFIZER INC. (US) 2010-04-08 WO disclosed
EP-1114823-A2 Substituted benzylamino nitrogen containing non-aromatic heterocycles PFIZER INC. (US) 2001-07-11 EP disclosed
US-5721255-A Substituted benzylamino nitrogen containing non-aromatic heterocycles PFIZER INC. (US) 1998-02-24 US disclosed
EP-0594636-B1 3-AMINOPIPERIDINE DERIVATIVES AND RELATED NITROGEN CONTAINING HETEROCYCLES PFIZER (US) 1998-01-21 EP disclosed
EP-0655996-A1 SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES PFIZER INC. (US) 1995-06-07 EP disclosed
WO-1994004496-A9 SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES 1995-01-26 WO disclosed
EP-0436334-B1 3-Aminopiperidine derivatives and related nitrogen containing heterocycles PFIZER (US) 1994-12-07 EP disclosed
US-5332817-A 3-aminopiperidine derivatives and related nitrogen containing heterocycles PFIZER INC. (US) 1994-07-26 US disclosed
EP-0594636-A1 3-AMINOPIPERIDINE DERIVATIVES AND RELATED NITROGEN CONTAINING HETEROCYCLES PFIZER INC. (US) 1994-05-04 EP disclosed
WO-1994004496-A1 SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES PFIZER INC. (US) 1994-03-03 WO disclosed
US-5232929-A 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use PFIZER INC. (US) 1993-08-03 US disclosed
WO-1993001170-A1 3-AMINOPIPERIDINE DERIVATIVES AND RELATED NITROGEN CONTAINING HETEROCYCLES PFIZER INC. (US) 1993-01-21 WO disclosed
WO-1991009844-A1 SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1991-07-11 WO disclosed
EP-0436334-A2 3-Aminopiperidine derivatives and related nitrogen containing heterocycles PFIZER INC. (US) 1991-07-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172297-A1 Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof GRIK5, GABRE, GRIK2 TP53 4131/4885MDM2 4630/4885DDB1 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.